Structure Therapeutics (GPCR) Competitors $23.70 +0.31 (+1.30%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$24.10 +0.41 (+1.71%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GPCR vs. ELAN, LNTH, NUVL, CYTK, VRNA, GRFS, TGTX, KRYS, SWTX, and BHVNShould you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include Elanco Animal Health (ELAN), Lantheus (LNTH), Nuvalent (NUVL), Cytokinetics (CYTK), Verona Pharma (VRNA), Grifols (GRFS), TG Therapeutics (TGTX), Krystal Biotech (KRYS), SpringWorks Therapeutics (SWTX), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry. Structure Therapeutics vs. Elanco Animal Health Lantheus Nuvalent Cytokinetics Verona Pharma Grifols TG Therapeutics Krystal Biotech SpringWorks Therapeutics Biohaven Structure Therapeutics (NASDAQ:GPCR) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, community ranking, institutional ownership and earnings. Do analysts rate GPCR or ELAN? Structure Therapeutics presently has a consensus target price of $81.29, indicating a potential upside of 243.05%. Elanco Animal Health has a consensus target price of $16.00, indicating a potential upside of 45.24%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Structure Therapeutics is more favorable than Elanco Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Elanco Animal Health 1 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25 Does the MarketBeat Community prefer GPCR or ELAN? Elanco Animal Health received 109 more outperform votes than Structure Therapeutics when rated by MarketBeat users. However, 88.24% of users gave Structure Therapeutics an outperform vote while only 54.51% of users gave Elanco Animal Health an outperform vote. CompanyUnderperformOutperformStructure TherapeuticsOutperform Votes3088.24% Underperform Votes411.76%Elanco Animal HealthOutperform Votes13954.51% Underperform Votes11645.49% Does the media prefer GPCR or ELAN? In the previous week, Elanco Animal Health had 8 more articles in the media than Structure Therapeutics. MarketBeat recorded 10 mentions for Elanco Animal Health and 2 mentions for Structure Therapeutics. Elanco Animal Health's average media sentiment score of 0.18 beat Structure Therapeutics' score of -0.03 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Elanco Animal Health 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of GPCR or ELAN? 91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 9.4% of Structure Therapeutics shares are owned by insiders. Comparatively, 0.6% of Elanco Animal Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings and valuation, GPCR or ELAN? Structure Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Structure Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStructure TherapeuticsN/AN/A-$89.62M-$0.74-32.02Elanco Animal Health$4.42B1.23-$1.23B$0.4027.54 Which has more volatility & risk, GPCR or ELAN? Structure Therapeutics has a beta of -2.75, indicating that its share price is 375% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Is GPCR or ELAN more profitable? Elanco Animal Health has a net margin of 4.60% compared to Structure Therapeutics' net margin of 0.00%. Elanco Animal Health's return on equity of 6.78% beat Structure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Structure TherapeuticsN/A -16.37% -15.68% Elanco Animal Health 4.60%6.78%3.03% SummaryElanco Animal Health beats Structure Therapeutics on 11 of the 17 factors compared between the two stocks. Get Structure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GPCR vs. The Competition Export to ExcelMetricStructure TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.36B$7.04B$5.77B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-32.026.1326.4618.82Price / SalesN/A311.27456.6780.61Price / CashN/A67.8344.0437.47Price / Book2.436.747.634.64Net Income-$89.62M$138.11M$3.18B$245.69M7 Day Performance-2.85%-2.43%-1.91%-2.66%1 Month Performance-15.19%-1.91%-0.19%-2.15%1 Year Performance-42.25%-5.03%16.70%12.90% Structure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GPCRStructure Therapeutics2.4917 of 5 stars$23.70+1.3%$81.29+243.1%-42.2%$1.36BN/A-32.02136ELANElanco Animal Health4.0515 of 5 stars$11.26-3.4%$16.29+44.7%-31.9%$5.57B$4.42B28.159,300Analyst ForecastLNTHLantheus4.5798 of 5 stars$79.94-2.5%$131.86+64.9%+37.9%$5.56B$1.30B13.30700Analyst RevisionPositive NewsNUVLNuvalent2.1211 of 5 stars$77.93-3.7%$112.36+44.2%-3.7%$5.54BN/A-22.4640Upcoming EarningsInsider TradeCYTKCytokinetics4.1857 of 5 stars$46.16+10.9%$82.00+77.6%-34.3%$5.45B$7.53M-8.58250High Trading VolumeVRNAVerona Pharma1.9444 of 5 stars$64.21+4.1%$57.14-11.0%+309.6%$5.13B$460,000.00-33.4430GRFSGrifols1.9016 of 5 stars$7.32-2.0%N/A-14.9%$5.03B$7.13B6.2023,737Upcoming EarningsTGTXTG Therapeutics4.4797 of 5 stars$30.71-0.1%$40.67+32.4%+137.2%$4.78B$233.66M-307.07290Positive NewsKRYSKrystal Biotech4.4745 of 5 stars$153.24-1.6%$206.67+34.9%+73.9%$4.41B$50.70M86.58210Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageSWTXSpringWorks Therapeutics1.2418 of 5 stars$57.43-2.0%$70.83+23.3%+18.4%$4.27B$5.45M-14.80230Earnings ReportAnalyst ForecastInsider TradeNews CoverageBHVNBiohaven3.3776 of 5 stars$41.45-0.8%$63.15+52.4%-20.8%$4.19BN/A-4.43239Short Interest ↓ Related Companies and Tools Related Companies Elanco Animal Health Alternatives Lantheus Alternatives Nuvalent Alternatives Cytokinetics Alternatives Verona Pharma Alternatives Grifols Alternatives TG Therapeutics Alternatives Krystal Biotech Alternatives SpringWorks Therapeutics Alternatives Biohaven Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GPCR) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GPCR Stock Alerts